Phaseline

Companies › Jacobio Pharmaceuticals

Jacobio Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JAB-8263–Phase 2Rheumatoid Arthritis (RA); NSCLCJun 2027
JAB-23E73
Pan-KRAS inhibitor
KRASPhase 1Advanced Solid Tumor; Advanced Solid Tumors; Metastatic Pancreatic Ductal AdenocarcinomaDec 2026
JAB-30355
TP53 Y220C mutant-selective stabilizer
TP53Phase 1Solid TumorsJan 2027
JAB-2485
Aurora A inhibitor
AURKAPhase 1Solid TumorsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06959615JAB-23E73Phase 1Advanced Solid TumorOncologyDec 2026
NCT06386146JAB-30355Phase 1Solid TumorsOncologyJan 2027
NCT07684157JAB-8263Phase 2Rheumatoid Arthritis (RA)ImmunologyJun 2027
NCT05490472JAB-2485Phase 1Solid TumorsOncologyAug 2027
NCT04686682JAB-8263Phase 1NSCLCOncologyJan 2028
NCT06973564JAB-23E73Phase 1Advanced Solid TumorsOncologyNov 2028
NCT07640295JAB-23E73Phase 1Metastatic Pancreatic Ductal AdenocarcinomaOncologyDec 2029

Targets

KRAS (1) AURKA (1) TP53 (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Companies built like this

Kumquat Biosciences Ranok Therapeutics (Hangzhou) Genfleet Therapeutics (Shanghai) Multitude Therapeutics Abbisko Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.